Invivyd Logo
WORKING TO FIGHT VIRAL THREATS

Press Releases

November 9, 2023

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 2, 2023

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

October 31, 2023

Invivyd to Participate in Upcoming Investor Conferences

September 11, 2023

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 

September 6, 2023

Invivyd to Participate in Upcoming Investor Conferences

September 5, 2023

Invivyd Appoints William Duke as Chief Financial Officer

August 10, 2023

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

August 3, 2023

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

July 27, 2023

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

July 17, 2023

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Displaying 1 - 10 of 25
Print
Contact IR
RSS
Email Alerts
Invivyd Logo

General inquiries: info@invivyd.com

Medical information inquiries: medinfo@invivyd.com

1601 Trapelo Rd.
Suite 178
Waltham, MA 02451

781.819.0080

Privacy Policy
Terms of Use
Cookie Policy
©2023 Invivyd.
Invivyd, Invymab and the Invivyd logo are trademarks of Invivyd, Inc.